Global Information
회사소개 | 문의 | 위시리스트

특발성(본태성) 고혈압 : 세계 임상시험 리뷰

Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2017

리서치사 GlobalData
발행일 2017년 10월 상품 코드 247625
페이지 정보 영문 587 Pages
가격
US $ 2,500 ₩ 2,977,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,954,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,931,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


특발성(본태성) 고혈압 : 세계 임상시험 리뷰 Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2017
발행일 : 2017년 10월 페이지 정보 : 영문 587 Pages

원인 불명인 고혈압은 특발성 고혈압으로 불리며 고혈압의 95%를 차지합니다. 고혈압으로 연결되는 원인 인자가 환자에 따라서 다른 장애입니다. 특발성 고혈압의 증후는 두통, 코피, 숨참, 권태감, 흉통 등입니다. 진단에는 신체 검사, 혈압 측정, 요검사, 혈액검사, 심전도 등을 이용합니다. 치료는 혈압 수준에 따라서 실시하며 약물 요법과 생활 습관 개선이 주가 됩니다. 합병증에는 죽상동맥경화증, 심장 발작, 뇌졸중, 심장 비대, 신장 장애 등이 있습니다.

특발성(본태성) 고혈압에 관한 임상 연구의 최신 동향에 대해 분석했으며, 질환 치료법 개요, G7 및 E7 국가의 임상시험 상황, 지역·단계(상)·진행 상황별 임상시험 건수, 유망한 스폰서, 각 기업 및 연구기관에서의 연구 진행 상황, 유망한 치료제 비교 등의 정보를 전해드립니다.

서론

  • 특발성(본태성) 고혈압
  • 본 보고서의 개요

각 지역의 임상시험 상황

  • 각국의 임상시험 건수와 평균 피험자수
    • 상위 5개국의 임상시험 건수 : 아시아태평양 지역
    • 상위 5개국의 임상시험 건수 : 유럽
    • 주요 국가의 임상시험 건수 : 북미
    • 상위 5개국의 임상시험 건수 : 중동/아프리카 지역
    • 상위 5개국의 임상시험 건수 : 중남미

G7 국가의 임상시험 건수 : 특발성(본태성) 고혈압 임상시험 건수의 심혈관 임상시험 건수에 대한 비율

단계(상)별 임상시험 건수 : G7 국가

G7 국가의 임상시험 건수 : 단계(상)별

E7 국가의 임상시험 건수 : 특발성(본태성) 고혈압 임상시험 건수의 심혈관 임상시험 건수에 대한 비율

단계(상)별 임상시험 건수 : E7 국가

E7 국가의 임상시험 건수 : 단계(상)별

단계(상)별 임상시험 건수

  • 단계(상)별 진행중인 임상시험 건수

진행 상황별 임상시험 건수

평가 항목별 임상시험 건수

미완료 임상시험

일정기간에 채용된 피험자수

스폰서 종류별 임상시험 건수

유망한 스폰서

임상시험 주요 참여 기업 - 특발성(본태성) 고혈압 치료제

유망한 치료제

임상시험 개요

  • 대표적인 기업의 임상시험 개요
    • Novartis AG
    • C. H. Boehringer Sohn AG & Co. KG
    • Takeda Pharmaceutical Company Limited
    • Daiichi-Sankyo
    • Merck & Co., Inc.
    • Medionics International Inc
    • Bayer AG
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Les Laboratoires Servier SAS
  • 대표적인 연구기관 및 병원의 임상시험 개요
    • Institut de Recherches Internationales Servier
    • Regional Hospital Holstebro
    • National Heart, Lung, and Blood Institute
    • University of Erlangen-Nurnberg
    • University of Pavia
    • St. George's University of London
    • Central South University
    • Ehime University Graduate School of Medicine
    • Komono Kosei Hospital
    • Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

5개 대표적인 임상시험 개요

도표

KSM 14.10.07

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

GlobalData's clinical trial report, "Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2017" provides an overview of Idiopathic (Essential) Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic (Essential) Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Idiopathic (Essential) Hypertension Therapeutics Clinical Trials 28
  • Prominent Drugs 30
  • Latest Clinical Trials News on Idiopathic (Essential) Hypertension 31
  • Sep 25, 2017: Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Study in Japan of Esaxerenone for Treatment of Essential Hypertension 31
  • Clinical Trial Profile Snapshots 32

Appendix 585

  • Abbreviations 585
  • Definitions 585
  • Research Methodology 586
  • Secondary Research 586
  • About GlobalData 587
  • Contact Us 587
  • Source 587

List of Tables

List of Tables

  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 15
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 18
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 13
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 15
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 18
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 586
Back to Top
전화 문의
F A Q